证券研究报告：医药生物 | 公司点评报告 发布时间：2025-10-09 股票投资评级 买入|首次覆盖 个股表现 公司基本情况 | 最新收盘价（港元） | 74.50 | | --- | --- | | 总股本/流通股本（亿股）12.28/12.28 | | | 总市值/流通市值（亿港 | 914.86/914.86 | | 元） | | | 52 周内最高/最低价 | 78.55/ 18.52 | | 资产负债率(%) | 29.94 | | 市盈率 62.9 | | | 第一大股东 | 药明生物技术有限公司 | 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:陈灿 SAC 登记编号:S1340525070001 Email:chencan@cnpsec.com 药明合联(2268.HK) 业绩维持快速增长，产能扩张节奏顺利 ⚫ 事件 公司公布 2025 年上半年业绩，25H1 实现收入 27.0 亿元（+62.2%， 同比增速，下同）、净利润 7.5 亿元（+52.7%）、不含利息收支经调整 净利润 7.3 亿元（+6 ...

证 券 研 究 报 告 毛戈平（01318.HK）2025 年中报点评 强推（维持） 渠道优势突出，品类拓展持续，香氛上新引擎 事项： 业绩一览：25H1 收入同比+31.3%、净利润同比+36.1%，业绩表现亮眼。毛戈 平 25H1 实现收入 25.9 亿（+31.3%），归母净利润 6.7 亿（+36.1%），经调净 利润 6.7 亿，符合市场预期。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入(百万) | 3,885 | 5,142 | 6,588 | | 8,273 | | 同比增速(%) | 34.6% | 32.4% | 28.1% | | 25.6% | | 归母净利润(百万) | 881 | 1,191 | 1,527 | | 1,936 | | 同比增速(%) | 33.0% | 35.3% | 28.2% | | 26.8% | | 每股盈利(元) | 1.84 | 2.43 | 3.12 | | 3. ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company’s PD-L1 small molecule inhibitor ABSK043 has received approval for clinical research to treat KRAS G12C mutated NSCLC in combination with the KRAS G12C inhibitor, adagrasib [1] - ABSK043 shows potential as a first-in-class (FIC) oral PD-L1 inhibitor, with no other oral PD-(L)1 drugs currently available globally [2] - The initial clinical data indicates a balance of efficacy and safety, with 87% of patients experiencing treatment-emergent adverse events (TEAEs) and no peripheral neuropathy observed [2] - ABSK043 is designed specifically for combination therapy, offering advantages such as a short half-life, reduced immunogenicity, and oral administration flexibility [3] - The market potential for ABSK043 is significant, targeting approximately 45%-60% of NSCLC cases, with ongoing clinical trials in various treatment settings [3] Financial Projections - The company is projected to achieve revenues of 630 million, 685 million, and 637 million yuan for the years 2025, 2026, and 2027 respectively [5] - Expected net profits for the same period are 45 million, 70 million, and 102 million yuan [5] - The target price for the stock is set at 22.88 HKD, with the current price at 19.62 HKD [5] Pipeline Developments - The company has several key assets nearing milestones, including: 1. KRAS-G12D inhibitor ABSK141, expected to receive IND approval in the second half of 2025 [4] 2. Pan-KRAS inhibitor ABSK211, anticipated to enter clinical stages in 2026 [4] 3. CSF-1R inhibitor ABSK021, with an NDA submission planned for the second half of 2025 [4] 4. A bispecific antibody-drug conjugate (BsADC) targeting two pan-cancer targets, expected to achieve preclinical candidate status in early 2026 [4]

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [1]. Core Insights - The company, Tehai International, serves as the overseas listing platform for Haidilao, leading the expansion of Chinese cuisine internationally. It aims to enhance its global store layout and accelerate the internationalization of Chinese dining [6][11]. - The overseas hot pot market is projected to reach a scale of $30 billion, supported by over 60 million overseas Chinese, with local consumers also contributing to brand expansion [6][41]. - Tehai International is positioned as the largest Chinese dining brand in international markets, leveraging its strong brand presence and operational capabilities [6][47]. Summary by Sections Company Overview - Tehai International operates as the overseas platform for Haidilao, with 122 stores globally as of 2024, focusing on direct operations and local product offerings [11][12]. - The company has achieved significant revenue growth, with a projected revenue of $778.31 million in 2024, reflecting a year-on-year increase of 13.07% [1][6]. Industry Overview - The report highlights that the internationalization of Chinese cuisine is timely, with Tehai International being a key player in this trend. The company is expected to benefit from the growing acceptance of hot pot among local consumers [6][37]. - The international Chinese dining market is characterized by low concentration, providing opportunities for growth, especially for standardized offerings like hot pot [6][45]. Competitive Advantages - Tehai International is recognized as the leading hot pot brand, with a robust operational framework and supply chain management that supports its international expansion [6][56]. - The company has optimized its store model, reducing the average return period to 5.1 years, and is enhancing customer engagement through localized services and cultural events [6][31]. Financial Analysis - The financial projections indicate a compound annual growth rate (CAGR) of 50.6% for net profit from 2025 to 2027, with expected profits of $49.45 million in 2025 [1][6]. - The report anticipates a steady increase in the number of overseas stores, reaching 149 by 2027, further solidifying the company's market position [6][11].

证券研究报告 | 2025年10月08日 快手-W（01024.HK） OpenAI 发布 Sora APP，AIGC 需求加速增长 1 优于大市 公司研究·海外公司快评 互联网·互联网Ⅱ 投资评级：优于大市（维持） 证券分析师： 张伦可 0755-81982651 zhanglunke@guosen.com.cn 执证编码：S0980521120004 证券分析师： 陈淑媛 021-60375431 chenshuyuan@guosen.com.cn 执证编码：S0980524030003 事项： OpenAI 于 2025 年 9 月 30 日发布的新一代视频生成模型 Sora 2 和 Sora APP，发布后在社交媒体火爆出圈。 国信互联网观点： 作为"世界模拟器"的升级版本，Sora 2 在图像分辨率、风格操控和指令遵循方面均有突破。Sora2 通过 整合音视频同步生成技术，实现画面与环境音、物体交互声及对话的匹配，并显著提升物理仿真精度，能 模拟体操动作、跳水力学等真实世界动态。 OpenAI 同步推出了独立的 Sora App，从工具到社交平台，构建了一个集创作、分发、互动于一体的 AI 原 生社 ...

Investment Rating - The investment rating for Kuaishou-W (01024.HK) is "Outperform the Market" (maintained) [2][7]. Core Insights - OpenAI's release of the Sora 2 video generation model and the Sora App is expected to significantly boost the demand for AI-generated content, creating new opportunities in the social media landscape [3][6]. - Sora 2 features advancements in image resolution, style control, and instruction adherence, integrating audio-visual synchronization to enhance realism in generated videos [4][5]. - The Sora App, designed similarly to TikTok, allows users to create and share AI-generated videos, fostering a new social ecosystem around AI content creation [5][6]. Summary by Sections Company Overview - Kuaishou is positioned as a leader in the AI video sector, with its AI-generated video capabilities showing strong performance and continuous improvement [6]. Market Dynamics - The introduction of Sora 2 is anticipated to reshape the short video ecosystem, potentially increasing the proportion of AI-generated content and narrowing the gap with platforms like Douyin [6]. Financial Projections - The financial outlook includes projected revenues of 660,257 million in 2024, increasing to 865,930 million by 2027, with a net profit growth rate of 68% in 2024 [19].

Investment Rating - The report upgrades the investment rating to "Buy" based on the smooth commercialization process of the company's core product [6] Core Insights - The company's core product, SKB264, has been recognized for its potential in treating EGFR mutation NSCLC, with two key clinical studies selected for presentation at the 2025 ESMO conference, highlighting its significance in the field [1][2] - SKB264 has received approval for 3L treatment of EGFR mutation NSCLC in mainland China and is making progress in earlier lines of treatment, with a 2L NSCLC indication submission accepted for priority review [2] - The clinical trial results for SKB264 show significant improvements in progression-free survival (PFS) compared to existing treatments, indicating its competitive edge in the market [2][4] - SKB264 demonstrates efficacy in treating rare EGFR mutations, providing new treatment options for patients lacking standard therapies [3] - The product has also shown promise in breast cancer treatment, with recent approvals and ongoing clinical trials indicating its potential in HR+/HER2- breast cancer [4][5] Financial Projections - Revenue projections for the company are estimated at 2.084 billion, 2.876 billion, and 4.663 billion yuan for the years 2025, 2026, and 2027 respectively, with net profits expected to improve significantly by 2027 [6]

Investment Rating - The report maintains a "Buy" investment rating for the company [5] Core Insights - The company, Zhouliufu, is a leading brand in the gold and jewelry industry, with a focus on both online and offline channels for growth [1][3] - The Chinese jewelry market is expected to grow from 728 billion yuan in 2024 to 937 billion yuan by 2029, with gold jewelry maintaining a dominant position [2][32] - The company has a total of 3,857 stores as of mid-2025, ranking fifth in the country, and is expanding its presence in high-end markets while optimizing its store model [3][4] Summary by Sections Company Overview - Zhouliufu was founded in 2004 and has established a strong presence in the gold and jewelry sector, focusing on cost-effective products for the lower-tier markets [17] - The company operates primarily through a franchise model, which has facilitated rapid expansion, with 3,857 stores nationwide by mid-2025 [17][25] Industry Analysis - The jewelry market in China is expanding, driven by consumer demand for gold, which accounted for 73% of the market retail sales value in 2024 [32][34] - The market is characterized by low concentration, with the top five brands holding a combined market share of 41% in gold jewelry [36] Business Model and Strategy - Zhouliufu leverages a dual-channel strategy, with significant growth in online sales, which accounted for 53% of total revenue by mid-2025 [25][45] - The company is focusing on product diversification and targeting young female consumers, with 80% of online users being women aged 18-35 [57] Financial Performance - The company forecasts steady revenue growth, with projected revenues of 64.11 billion yuan in 2025, reflecting a year-on-year increase of 12.11% [11] - The earnings per share (EPS) for 2025 is estimated at 1.82 yuan, with a price-to-earnings (PE) ratio of 23 times [4][11] Market Position - Zhouliufu's market strategy includes expanding into high-end markets while maintaining a strong foothold in lower-tier cities, with a significant number of stores in these areas [50] - The company is actively enhancing its brand image through various marketing initiatives and collaborations, aiming to strengthen its market position [55][56]

IPO 申购指南 云迹科技（2670.HK） 建议谨慎申购 2025-10-8 星期三 【申购建议】 公司是领先的机器人服务 AI 赋能技术企业。公司主要提供机器人及功能套 件，辅以 AI 数字化系统的服务。从能够与现实世界互动的机器人，到能够 优化决策的 AI 数字化系统，公司向客户提供适应性强及可扩展的产品及服 务。根据弗若斯特沙利文的资料，2024 年，在机器人智能体市场拥有可适应 三维多层空间的机器人的参与者中，公司的同时在线机器人日均数量达到 27,000 台及服务消费者数量达到 2.3 亿人次，排名全球第一。于 2024 年，公 司的同时在线机器人数量单日高峰超过 36,000 台。 全球智能体市场按收入计的市场规模由 2020 年的人民币 390 亿元增至 2024 年的人民币 946 亿元，且预计于 2029 年达到人民币 6,020 亿元，2024 年至 2029 年的年复合增长率将加速至 44.8%，这表明全球智能体的采纳及应用呈 显著上升趋势。按收入计，全球有实体机器人形态的智能体市场已由 2020 年 的人民币 378 亿元增至 2024 年的人民币 820 亿元，年复合增长率为 21 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [5][20]. Core Insights - The company's revenue for the first half of 2025 remained stable at 6.644 billion, with a year-on-year decline in net profit attributable to shareholders of 9.0% [1][7]. - The medical device segment showed stable pricing, while the pharmaceutical packaging segment saw a significant increase in overseas sales, with the "ship-to-ship" sales ratio rising to 35%, an increase of nearly 10 percentage points year-on-year [2][10]. - The company has established a multi-dimensional barrier with brand image, quality control, scale effect, and cost advantages, indicating strong growth potential and industry leadership [20]. Revenue and Profitability - The company's revenue for the first half of 2025 was 66.44 billion (+0.1%), while the net profit attributable to shareholders was 10.08 billion (-9.0%), with a 12.7% decline after excluding one-time impacts [1][7]. - The gross profit margin decreased to 49.7% (down 1.2 percentage points year-on-year), reflecting pricing pressures on products [3][14]. - The net profit margin fell to 15.9% (down 1.5 percentage points year-on-year) [3][14]. Segment Performance - The medical device business generated approximately 33.0 billion in revenue, remaining stable year-on-year, but the segment profit decreased by 17.1% due to price declines and foreign exchange losses [2][10]. - The orthopedic business revenue was 7.3 billion (-1.6%), primarily due to a change in sales model for joint products, leading to lower factory prices [11]. - The interventional business revenue was 9.9 billion (-2%), with growth in the U.S., Europe, Middle East, and Africa regions [11]. Financial Forecasts - The revenue forecasts for 2025-2027 are adjusted to 137.6 billion, 148.5 billion, and 159.6 billion, with year-on-year growth rates of 5.1%, 8.0%, and 7.4% respectively [20]. - The net profit forecasts for the same period are 21.2 billion, 24.0 billion, and 26.8 billion, with year-on-year growth rates of 2.3%, 13.4%, and 11.6% respectively [20]. Cash Flow and Dividends - The operating cash flow for the first half of 2025 was 8.82 billion, with a cash content of net profit reaching 87%, indicating a healthy cash flow position [18]. - The board proposed a dividend of 4.42 billion for the first half of the year, maintaining a 50% payout ratio based on operating net profit [1][7].